Publications

Detailed Information

The Effects of Genetic Polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced Gastroduodenal Diseases in Korea

DC Field Value Language
dc.contributor.authorKang, Jung Mook-
dc.contributor.authorKim, Nayoung-
dc.contributor.authorLee, Dong Ho-
dc.contributor.authorPark, Ji Hyun-
dc.contributor.authorKim, Joo Sung-
dc.contributor.authorSong, In Sung-
dc.contributor.authorJung, Hyun Chae-
dc.contributor.authorLee, Mi Kyoung-
dc.date.accessioned2012-05-24T07:06:39Z-
dc.date.available2012-05-24T07:06:39Z-
dc.date.issued2009-06-
dc.identifier.citationJOURNAL OF CLINICAL GASTROENTEROLOGY; Vol.43 5; 420-428ko_KR
dc.identifier.issn0192-0790-
dc.identifier.urihttps://hdl.handle.net/10371/76433-
dc.description.abstractBackground: The genes that encode proinflammatory and antiinflammatory cytokines are good candidate markers of host susceptibility to gastroduodenal disease. The present study was performed to evaluate whether or not the genetic polymorphisms of IL-6, IL-8, and IL-10 are associated with gastroduodenal disease in the Korean population. Methods: This study enrolled 1187 patients, including controls, those with gastric cancer (GC), benign gastric ulcer (BGU), and duodenal ulcer patients. Six polymorphisms were genotyped, 3 of IL-10 (at -592, -819, and -1082), 1 of IL-8 (at -251), and 2 of IL-6 (at -174 and -572) by polymerase chain reaction-restriction fragment length polymorphism analysis. Results: The frequency of IL-10-1082 G carriers was higher in cases of a diffuse type GC [odds ratio (OR) 1.81 95% confidence interval (CI): 1.0-3.1, P = 0.041] or BGU (OR 1.6, 95% Cl: 1.0-2.5, P = 0.040), than in the control group regardless of Helicobacter pylori infection. The IL-8-251 A/A genotype was more common in H. pylori-positive patients with GC (OR 2.0, 95% Cl: 1.2-3.6, P = 0.013) or BGU (OR 2.7 95% Cl: 1.5-4.8, P = 0.001) than in H. pylori-positive controls. In addition, the frequencies of IL-6-572 G/G (OR 0.3, 95% Cl: 0.1-0.9 P = 0.027) and of G carriers (OR 0.5, 95% Cl: 0.4-0.8, P = 0.003) were lower in H. pylori-positive duodenal ulcer patients than in H. pylori-positive controls. IL-10-592 C/C (OR 0.4, 95% Cl: 0.2-0.9. P = 0.028) was an independent factor associated with a decreased risk of the intestinal type of GC by multivariate analysis. Furthermore, a synergistic effect was observed between IL-10-592 A/A and IL-8-251 A/A with respect to the development of GC or BGU. Conclusions: These results suggest that the genetic polymorphisms of these 3 inflammation-related cytokines, IL-10, IL-8. and IL-6, are associated with the development of H. pylori-associated gastroduodenal disease.ko_KR
dc.description.sponsorshipSupported by the Korean Health 21 R&D Project, Ministry of Health
and Welfare, Republic of Korea (no. A060266) and by grant no. 06-
2006-009 from the Seoul National University Bundang Hospital
Research fund.
ko_KR
dc.language.isoenko_KR
dc.publisherLIPPINCOTT WILLIAMS & WILKINSko_KR
dc.subjectHelicobacter pyloriko_KR
dc.subjectIL-6ko_KR
dc.subjectIL-8ko_KR
dc.subjectgenetic polymorphismko_KR
dc.subjectIL-10ko_KR
dc.titleThe Effects of Genetic Polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced Gastroduodenal Diseases in Koreako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor강정묵-
dc.contributor.AlternativeAuthor김나영-
dc.contributor.AlternativeAuthor이동호-
dc.contributor.AlternativeAuthor박지현-
dc.contributor.AlternativeAuthor이미경-
dc.contributor.AlternativeAuthor김주성-
dc.contributor.AlternativeAuthor정현채-
dc.contributor.AlternativeAuthor송인성-
dc.citation.journaltitleJOURNAL OF CLINICAL GASTROENTEROLOGY-
dc.description.citedreferenceSugimoto M, 2007, J GASTROEN HEPATOL, V22, P1443, DOI 10.1111/j.1440-1746.2006.04613.x-
dc.description.citedreferenceGarcia-Gonzalez MA, 2007, AM J GASTROENTEROL, V102, P1878, DOI 10.1111/j.1572-0241.2007.01423.x-
dc.description.citedreferenceGatti LL, 2007, ARCH MED RES, V38, P551, DOI 10.1016/j.arcmed.2006.12.011-
dc.description.citedreferenceLeung WK, 2006, AM J GASTROENTEROL, V101, P714, DOI 10.1111/j.1572-0241.2006.00560.x-
dc.description.citedreferenceKim N, 2006, HELICOBACTER, V11, P105-
dc.description.citedreferenceKamangar F, 2006, CANCER CAUSE CONTROL, V17, P117, DOI 10.1007/s10552-005-0439-7-
dc.description.citedreferenceTaguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326-
dc.description.citedreferenceLee WP, 2005, CLIN CANCER RES, V11, P6431, DOI 10.1158/1078-0432.CCR-05-0942-
dc.description.citedreferenceLee JY, 2005, CANCER LETT, V225, P207, DOI 10.1016/j.canlet.2004.11.028-
dc.description.citedreferenceGarza-Gonzalez E, 2005, INT J CANCER, V114, P237, DOI 10.1002/ijc.20718-
dc.description.citedreferenceOhyauchi M, 2005, GUT, V54, P330, DOI 10.1136/gut.2003.033050-
dc.description.citedreferenceLu WL, 2005, CARCINOGENESIS, V26, P631, DOI 10.1093/carcin/bgh349-
dc.description.citedreferenceZambon CF, 2005, CYTOKINE, V29, P141, DOI 10.1016/j.cyto.10.013-
dc.description.citedreferenceHsu PI, 2004, HELICOBACTER, V9, P605-
dc.description.citedreferenceJerrard-Dunne P, 2004, STROKE, V35, P2438, DOI 10.1161/01.STR.0000144681.46696.b3-
dc.description.citedreferenceRad R, 2004, GUT, V53, P1082, DOI 10.1136/gut.2003.029736-
dc.description.citedreferenceEck M, 2003, CLIN EXP IMMUNOL, V134, P508, DOI 10.1046/j.1365-2249.2003.02305.x-
dc.description.citedreferenceGarcia-Gonzalez MA, 2003, CLIN EXP IMMUNOL, V134, P525, DOI 10.1046/j.1365-2249.2003.02325.x-
dc.description.citedreferenceEl-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4-
dc.description.citedreferenceWu MS, 2003, INT J CANCER, V104, P617, DOI 10.1002/ijc.10987-
dc.description.citedreferenceSuarez A, 2003, TRANSPLANTATION, V75, P711, DOI 10.1097/01.TP.0000055216.19866.9A-
dc.description.citedreferenceMoraes MO, 2003, IMMUNOGENETICS, V54, P896, DOI 10.1007/s00251-003-0543-3-
dc.description.citedreferenceFuruta T, 2002, GASTROENTEROLOGY, V123, P92, DOI 10.1053/gast.2002.34156-
dc.description.citedreferenceWu MS, 2002, J INFECT DIS, V185, P106-
dc.description.citedreferenceLanas A, 2001, GENES IMMUN, V2, P415-
dc.description.citedreferenceLauta VM, 2001, CYTOKINE, V16, P79-
dc.description.citedreferenceKato S, 2001, J GASTROENTEROL, V36, P696-
dc.description.citedreferenceMachado JC, 2001, GASTROENTEROLOGY, V121, P823, DOI 10.1053/gast.2001.28000-
dc.description.citedreferenceUemura N, 2001, NEW ENGL J MED, V345, P784-
dc.description.citedreferenceGarcia-Gonzalez MA, 2001, CLIN EXP IMMUNOL, V125, P368, DOI 10.1046/j.1365-2249.2001.01593.x-
dc.description.citedreferenceDe Vita F, 2001, J INTERF CYTOK RES, V21, P45-
dc.description.citedreferenceHull J, 2000, THORAX, V55, P1023-
dc.description.citedreferenceTerry CF, 2000, J BIOL CHEM, V275, P18138-
dc.description.citedreferenceEl-Omar EM, 2000, NATURE, V404, P398-
dc.description.citedreferenceFishman D, 1998, J CLIN INVEST, V102, P1369-
dc.description.citedreferenceTurner DM, 1997, EUR J IMMUNOGENET, V24, P1-
dc.description.citedreferenceHopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244-
dc.description.citedreferenceKUIPERS EJ, 1995, LANCET, V345, P1525-
dc.description.citedreferenceCRABTREE JE, 1994, EUR J GASTROEN HEPAT, V6, pS33-
dc.description.citedreferenceCRAIG PM, 1992, GUT, V33, P1020-
dc.description.citedreferenceCRABTREE JE, 1991, GUT, V32, P1473-
dc.description.citedreferenceSEHGAL PB, 1986, P NATL ACAD SCI USA, V83, P5319-
dc.description.tc14-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share